{
    "organizations": [],
    "uuid": "94c16d6f4c205a0d7aeb3f613930dd4532eaf2e5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alexion-says-no-compulsory-license/brief-alexion-says-no-compulsory-license-of-soliris-was-requested-or-granted-in-brazil-idUSFWN1RX0ZF",
    "ord_in_thread": 0,
    "title": "BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20, 2018 / 7:40 PM / Updated 6 minutes ago BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil Reuters Staff \nApril 20 (Reuters) - Alexion Pharmaceuticals Inc: \n* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRISÂ® (ECULIZUMAB) \n* ALEXION PHARMACEUTICALS - ALEXION WOULD LIKE TO CLARIFY THAT NO COMPULSORY LICENSE OF SOLIRIS WAS REQUESTED OR GRANTED IN BRAZIL \n* ALEXION PHARMACEUTICALS INC - CONTINUES TO HAVE PATENT APPLICATIONS PENDING IN BRAZIL THAT WOULD PROVIDE ADDITIONAL PROTECTION TO SOLIRIS Source text for Eikon: Further company coverage:",
    "published": "2018-04-20T22:40:00.000+03:00",
    "crawled": "2018-04-20T22:58:02.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "compulsory",
        "license",
        "soliris",
        "requested",
        "granted",
        "brazil",
        "reuters",
        "staff",
        "april",
        "reuters",
        "alexion",
        "pharmaceutical",
        "inc",
        "alexion",
        "provides",
        "statement",
        "superior",
        "court",
        "justice",
        "stj",
        "decision",
        "brazil",
        "involving",
        "eculizumab",
        "alexion",
        "pharmaceutical",
        "alexion",
        "would",
        "like",
        "clarify",
        "compulsory",
        "license",
        "soliris",
        "requested",
        "granted",
        "brazil",
        "alexion",
        "pharmaceutical",
        "inc",
        "continues",
        "patent",
        "application",
        "pending",
        "brazil",
        "would",
        "provide",
        "additional",
        "protection",
        "soliris",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}